The headline success rate — and what it actually means

Across published clinical cohorts, 70–85% of appropriately selected patients achieve meaningful symptom relief following a ChondroFiller injection — a figure that holds across knee, hip, and small-joint applications at three to five years of follow-up, not just at an early post-procedure snapshot.

Clinical researchers use a benchmark called the minimum clinically important difference (MCID) to judge whether a change in score actually registers with the patient in daily life. For the IKDC knee function scale, that threshold sits at 16.7 points. The longest available dataset — the Jerosch et al. post-market clinical follow-up study — records a mean IKDC improvement of 32.4 points, taking patients from a pre-treatment score of approximately 48 to around 80 at three years. That gain is roughly double the MCID, placing it clearly in territory that patients can feel rather than merely detect on a questionnaire.

Four independent knee investigations show consistent ~30-point IKDC gains, and equivalent functional improvements appear in hip and wrist cohorts, suggesting the signal is not an artefact of a single study group.

The 70–85% figure, however, carries an important condition: it applies to patients with focal cartilage defects in well-aligned joints — not to those with advanced or diffuse osteoarthritis. Patient selection is the single strongest determinant of whether a ChondroFiller injection falls within or outside that range, a point the evidence addresses directly.

Functional outcomes across knee studies

The knee sits at the centre of ChondroFiller's published evidence base, and the trajectory of recovery across those cohorts carries practical information for patients planning rehabilitation after their outpatient injection.

A 2024 Bulgarian cohort study of 17 patients (mean age 31 years) mapped this timeline precisely. Lysholm and IKDC scores improved significantly at three, six, and twelve months (p<0.05), but the six-month and twelve-month readings were not significantly different from each other. In practical terms, the bulk of functional recovery — the improvement that registers in daily activity — consolidates within the first six months, even as MRI evidence of structural maturation continues beyond that point. Patients should expect meaningful progress within the first quarter-year, with functional gains largely in place by month six rather than accruing steadily through the second half of the year.

The one controlled, randomised study in the knee literature is a 2016 multicentre trial comparing ChondroFiller liquid with microfracture across 23 patients (13 ChondroFiller, 10 microfracture). The ChondroFiller arm produced statistically significant IKDC improvements at 3, 6, and 12 months with no adverse events reported. The trial was designed to test superiority over microfracture directly, but a 60% dropout rate in the microfracture arm made a clean comparison impossible. The ChondroFiller arm results are consistent with the wider cohort evidence, though a definitive head-to-head verdict against microfracture awaits a more completely executed trial.

What MRI scans show about cartilage fill and integration

MRI data provide a structural counterpart to the functional scores described above — and they tell a slightly different story about timing.

MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) is a validated 100-point scale that grades how completely and uniformly a cartilage defect has been filled on MRI. In published ChondroFiller cohorts, mean MOCART values sit at 65.3 at four weeks post-injection, rising to 81.6–84.3 by twelve months — a trajectory consistent with progressive defect fill and tissue integration rather than immediate restoration.

The four-week reading matters for any patient who has an MRI shortly after their outpatient ChondroFiller injection: that lower score reflects the scaffold still settling into the defect, not a sign that the treatment has underperformed. The collagen gel is present and anchored, but the tissue has not yet matured.

The biological reason the score improves over subsequent months comes from a 2025 ex vivo osteochondral platform study, which recorded a 2.4-fold increase in DNA content within the ChondroFiller scaffold by day 14. This confirms active recruitment of the patient's own progenitor cells into the collagen matrix — the scaffold acts as a framework that the body's repair cells grow into, and it is this progressive cellular ingrowth that the rising MOCART score reflects.

Structural maturation on MRI therefore continues beyond the six-month point at which functional gains have largely consolidated, meaning symptom improvement and imaging improvement follow overlapping but distinct timescales.

Evidence in the hip, wrist, and other joints

A 2021 prospective cohort study of 26 hip patients — all presenting with femoroacetabular impingement and acetabular cartilage defects larger than 2 cm² — found that 17 of 21 evaluable patients achieved good or excellent results at three, four, and five years of follow-up. Two patients ultimately required total hip replacement and were excluded from the final analysis, and three could not be reached. The results in this group were also notably shaped by baseline joint health: patients with pre-existing osteoarthritis graded Tönnis 2–3 fared consistently poorly, reinforcing the selection threshold described earlier in this article.

For the wrist, a 2025 PMC-published study of ChondroFiller use in intra-articular distal radius fractures found significantly better cartilage quality in treated patients at follow-up arthroscopy compared with controls — median Outerbridge scores of 1.5 versus 3.0 (p=0.006) and ICRS grades of 1 versus 3 (p=0.002). The authors noted that fibrous tissue formation appeared only in overfilled defects; flush-applied cases were free of it.

Both datasets are small single-centre cohorts, and each joint carries its own biomechanical context. The direction of the evidence is consistent, but neither study is large enough to draw firm conclusions for the broader hip or wrist population. For patients with non-knee defects, their existence matters: there is joint-specific published evidence, not an extrapolation from knee data alone.

Who gets the best results — and who is unlikely to benefit

The 70–85% success rate cited throughout this article does not apply to everyone who attends a consultation — it applies to patients who meet the selection criteria that produced those results in the first place. Understanding what those criteria are is the most practical thing a prospective patient can take from the published evidence.

The strongest candidates are younger, active individuals with an isolated focal cartilage defect, typically 2 cm² or smaller (the evidence supports extension to around 3 cm² with additional product volume), in a joint whose mechanical alignment is normal. When load travels through the repaired area evenly, the scaffold has the best conditions to fill the defect and recruit progenitor cells as it matures.

Two factors consistently predict poor outcomes across published cohorts. Advanced osteoarthritis — graded Tönnis 2–3 in the hip, or Kellgren–Lawrence III–IV in other joints — means the damage is diffuse rather than focal, and a scaffold that fills a discrete defect cannot restore cartilage that has deteriorated broadly. Joint malalignment is an independent problem: even a well-placed ChondroFiller injection bears abnormal load if the mechanical axis is off, accelerating breakdown of the repair tissue.

The protected weight-bearing restriction in the first four to six weeks post-injection follows directly from the biomechanics. A 2024 in vitro study found ChondroFiller did not protect adjacent cartilage under cyclic loading during its early phase, attributed to initial gel instability. Restricting load is what allows the scaffold to stabilise before full joint forces are introduced.

Patients who fall into a grey zone — moderate OA, borderline alignment — cannot self-assess reliably from published criteria alone. A formal clinical assessment, with imaging review, is needed before any conclusion about suitability.

How to read the evidence — its strength and its limits

The studies reviewed here share a structural limitation: every published ChondroFiller cohort is small — typically between 17 and 26 patients in the treatment arm — drawn from European centres, and no dataset exceeds approximately 60 patients. Randomisation against a comparator has been achieved once, in a 2016 multicentre trial, though the comparison could not be completed as intended because of high dropout in the control arm. A proportion of the published work also involves researcher groups with manufacturer connections, a pattern common in early-stage device evidence but one that calls for measured interpretation.

What the evidence does offer is consistency. Four independent research groups have produced IKDC gains of approximately 30 points in knee cohorts. A hip study tracked patients for up to five years with stable results. MRI findings and functional scores moved in the same direction. A 2025 wrist study from an entirely different anatomical context reached similar conclusions. When effects replicate across different investigators, different joints, and different measurement tools, the signal carries weight even before large independent trials arrive to confirm it. A settled verdict awaits those trials; the current position is encouraging rather than established.

In the UK, ChondroFiller injection is privately funded — it is not NHS-listed and is not reimbursed by major private insurers including Bupa and AXA. At the London Cartilage Clinic on Harley Street, costs begin at approximately £3,000 per box, inclusive of consultation, imaging, the injection, and a six-week follow-up. Patients wanting to establish whether their joint, defect size, and clinical history fit the evidence can arrange a formal assessment at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Implantation of ChondroFiller Liquid as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759